Clinical Trials

Phase 1/2 Active not recruiting

Lymphoma, Mantle-Cell

NCT02427451 2026-01-27

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

87 enrolled 30 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Phase 1/2 Recruiting

40 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04446962 2025-09-25

LOC-R01

118 enrolled

CNSLymphoid

Lymphoma, Neurologic Manifestations, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms

NCT02315768 2025-09-15

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

32 enrolled 9 charts

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02558816 2025-07-24

OAsIs

48 enrolled

Lymphoma, Mantle-Cell

NCT02956382 2025-07-18

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

24 enrolled 18 charts

Lymphoma, Lymphoma, Follicular, Recurrence

NCT02899078 2025-05-18

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

31 enrolled 11 charts

Genitourinary

Carcinoma, Renal Cell

NCT03129828 2024-12-13

ImbruVeRCHOP

38 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02927964 2024-10-16

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

21 enrolled 11 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03323151 2024-01-18

PrE0404

43 enrolled 21 charts

Lymphoma, Mantle-Cell

NCT02321540 2023-10-25

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

13 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04522284 2023-03-29

PRECISE CURATE.AI Pilot Clinical Trial

Phase 1/2 Unknown

20 enrolled

Waldenstrom Macroglobulinemia, Neoplasms

NCT03877055 2022-12-14

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

8 enrolled 7 charts

Lymphoma, Mantle-Cell

NCT03332498 2022-06-03

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

40 enrolled 12 charts

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Colorectal Neoplasms

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1/2 Terminated

58 enrolled

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell

NCT02562898 2021-05-06

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

18 enrolled 15 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT04771507 2021-02-25

IbruOnOff

Phase 1/2 Recruiting

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01752426 2020-02-24

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

30 enrolled 9 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02677948 2017-09-06

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Phase 1/2 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02912754 2017-03-13

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

Phase 1/2 Unknown

36 enrolled